Australia is showing great interest in the arrival of Retatrutide, a novel medication by Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, has shown remarkable results in clinical trials, https://siobhanuggh401432.vigilwiki.com/7992394/novo_nordisk_s_retatrutide_australia_a_promising_hope_for_obesity_treatment